476 filings
Page 2 of 24
POS AM
9r62fup6
2 Mar 23
Prospectus update (post-effective amendment)
4:44pm
25-NSE
t9wwiwuo8b9d
2 Mar 23
Exchange delisting
4:30pm
8-K
iovrrpoahh e38j8
2 Mar 23
Completion of Acquisition or Disposition of Assets
4:27pm
SC 14D9/A
vf1t b3xj
2 Mar 23
Tender offer solicitation (amended)
11:28am
SC TO-T/A
p21kpsqynx
2 Mar 23
Third party tender offer statement (amended)
11:23am
SC 14D9/A
mi0e4cu74y9ch61cpadr
22 Feb 23
Tender offer solicitation (amended)
6:33am
SC TO-T/A
50w 9tuom1
22 Feb 23
Third party tender offer statement (amended)
6:19am
8-K
gayrhvmw2otzh316
14 Feb 23
Other Events
8:38am
SC 14D9/A
vyttgn cu8
30 Jan 23
Tender offer solicitation (amended)
6:29pm
SC 14D9
xb7sei583pvu
23 Jan 23
Tender offer solicitation
8:59am
SC TO-T
yayofp
23 Jan 23
Third party tender offer statement
8:11am
SC14D9C
3ojsrpkk
19 Jan 23
Written communication relating to third party tender offer
4:10pm
SC TO-C
tk815m
10 Jan 23
Information about tender offer
6:06am
SC TO-C
hfgcmo46bto6nl48a9x
9 Jan 23
Information about tender offer
7:30am
SC14D9C
cf63io
9 Jan 23
Written communication relating to third party tender offer
6:13am
8-K
zjxm2dy
9 Jan 23
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
6:05am
8-K
0f1uq28zc0m877s
6 Dec 22
Departure of Directors or Certain Officers
8:37am
8-K
yujw7mcb e1s8
8 Nov 22
Albireo Reports Q3 2022 Financial Results and Business Update
4:07pm
8-K
ob2ovq6qmr296zycajoo
11 Oct 22
Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome
8:25am